1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Savella (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Savella (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly’s Cymbalta, and Otsuka/BMS’s Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda’s Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Savella (minlacipran) is an SNRI indicated for the treatment of depression, but only in Japan. Savella is available in the US, but is only indicated for the treatment of fibromyalgia. Savella has not been granted marketing approval by the European Medicine Agency (EMA) for any indication, but it is available in France for the treatment of MDD. It was initially developed by Cypress Bioscience, which was later wholly acquired by Royalty Pharma. Savella, which is known as Toledomin in Japan, was the first SNRI to become available in the Japanese market; it was launched in Japan in 2008.

Scope

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Savella including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Savella for the top three countries from 2013 to 2023.
- Sales information covered for the US, France and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Savella performance
- Obtain sales forecast for Savella from 2013-2023 in the top three countries (the US, France and Japan)

Table Of Contents

Savella (Major Depressive Disorder) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 11
3.2 Classification 13
3.3 Symptoms and Subtypes of Major Depressive Disorder 15
3.4 Prognosis 16
3.5 Quality of Life 16
4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Diagnosis 17
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 18
4.1.3 Clinical Practice 21
5 Competitive Assessment 26
5.1 Overview 26
6 Savella (Milnacipran) 28
6.1 Overview 28
6.2 Efficacy 29
6.3 Safety 29
6.4 SWOT Analysis 30
6.5 Forecast 30
7 Appendix 32
7.1 Bibliography 32
7.2 Abbreviations 34
7.3 Methodology 36
7.4 Forecasting Methodology 36
7.4.1 Diagnosed MDD Patients 36
7.4.2 Percent of Drug-Treated Patients 36
7.4.3 General Pricing Assumptions 37
7.4.4 Individual Drug Assumptions 37
7.4.5 Generic Erosion 38
7.5 Physicians and Specialists Included in this Study 39
7.6 About the Authors 41
7.6.1 Analyst 41
7.6.2 Therapy Area Directors 41
7.6.3 Global Head of Healthcare 42
7.7 About GlobalData 43
7.8 Disclaimer 43

1.1 List of Tables

Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10) 14
Table 2: Subtypes of Major Depressive Disorder 15
Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria 17
Table 4: Treatment Guidelines for Major Depressive Disorder 19
Table 5: Most Prescribed Drugs for MDD by Class in the 7MM and Australia, 2013 21
Table 6: Leading Treatments for MDD, 2013 27
Table 7: Product Profile - Savella 28
Table 8: Savella SWOT Analysis, 2014 30
Table 9: Global Sales Forecasts ($m) for Savella, 2013-2023 31
Table 10: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 40

1.2 List of Figures

Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons 13
Figure 2: Disease Management Model for Major Depressive Disorder 23
Figure 3: Major Depressive Disorder Treatment Algorithm 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Major Depressive Disorder - Market Insights, Epidemiology and Market Forecast-2023

Major Depressive Disorder - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Major Depressive Disorder - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2025

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2025

  • $ 3995
  • Industry report
  • October 2016
  • by Global Data

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2025 Summary Major depressive disorder (MDD), also known as clinical depression or major depression, is widely recognized as a mood ...

Major Depressive Disorder - Epidemiology Forecast To 2023

Major Depressive Disorder - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Major Depressive Disorder - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Major Depressive Disorder in seven major markets (US, France, Germany, Italy, ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.